Shanghai-based Excalipoint secures rights to two preclinical T-cell engagers from Lepu Biopharma, aiming to fast-track development for solid tumors and hematologic malignancies.
Blog Page 3
Phase 2 study for Caliway’s CBL-514 highlights significant progress for Dercum’s disease, a rare and painful condition with no approved therapies
A phase 1 pilot trial suggests that a novel egg-shell derived peptide may reduce Alzheimer’s biomarkers and improve memory in mild Alzheimer’s patients
The company is cutting operating costs while preserving investment in casdozokitug and tagmokitug, with mature clinical updates expected in the second half of 2026
The oncology company reported $1.7 billion in quarterly revenue and lifted full-year guidance as its flagship BTK inhibitor continued expanding globally
An August 5 public meeting convened by the Reagan-Udall Foundation for the FDA examined how approved medicines could be prioritised for new uses without weakening standards for safety and effectiveness
Health Canada authorized the Phase 1 study of mRNA-1469 as an active outbreak in the Democratic Republic of the Congo and Uganda tests how quickly vaccine platforms can move from sequence to clinical evidence
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, and product ownership
A Delaware jury awarded Yale and Biohaven $4 million after finding that Avilar Therapeutics and RA Capital willfully misappropriated a targeted protein degradation trade secret